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Protein synthesis inhibitors have long
been known to prevent G2 phase cells
from entering mitosis. Lockhead et al.
demonstrate that this G2 arrest is due to
the activation of p38 MAPK, not
insufficient protein synthesis, arguing
that protein synthesis in G2 phase is not
absolutely required for mitotic entry.ll
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https://doi.org/10.1016/j.celrep.2020.107901SUMMARYProtein synthesis inhibitors (e.g., cycloheximide) block mitotic entry, suggesting that cell cycle progression
requires protein synthesis until right before mitosis. However, cycloheximide is also known to activate p38
mitogen-activated protein kinase (MAPK), which can delay mitotic entry through a G2/M checkpoint. Here,
we ask whether checkpoint activation or a requirement for protein synthesis is responsible for the cyclohex-
imide effect. We find that p38 inhibitors prevent cycloheximide-treated cells from arresting in G2 phase and
that G2 duration is normal in approximately half of these cells. The Wee1 inhibitor MK-1775 and Wee1/Myt1
inhibitor PD0166285 also prevent cycloheximide from blockingmitotic entry, raising the possibility thatWee1
and/or Myt1 mediate the cycloheximide-induced G2 arrest. Thus, protein synthesis during G2 phase is not
required for mitotic entry, at least when the p38 checkpoint pathway is abrogated. However, M phase pro-
gression is delayed in cycloheximide-plus-kinase-inhibitor-treated cells, emphasizing the different require-
ments of protein synthesis for timely entry and completion of mitosis.INTRODUCTION
Early studies on human cells in tissue culture as well as cells in
the intestinal crypt of rats demonstrated that protein synthesis
inhibitors, like cycloheximide and puromycin, prevent cells
from entering mitosis, unless the cells were already in late G2
phase at the time of treatment (Donnelly and Sisken, 1967; Ver-
bin and Farber, 1967). The discovery ofmitotic cyclins, activators
of the cyclin-dependent kinases (Cdks), which accumulate prior
to mitosis, provided a plausible explanation for these observa-
tions (Evans et al., 1983; Moreno et al., 1989; Morgan, 2007).
Indeed, supplementing a cycloheximide-arrested Xenopus lae-
vis egg extract with exogenous cyclin B is sufficient to promote
mitotic progression (Murray et al., 1989), as is supplementing
an RNase-treated extract with cyclin B mRNA (Murray and
Kirschner, 1989), and blocking the synthesis of cyclin B1 and
B2 prevents mitotic entry (Minshull et al., 1989). This argues
that the synthesis of this particular protein is of singular impor-
tance for M phase initiation.
In human cells, mitotic cyclins, mainly cyclins A2, B1, and B2,
start to accumulate around the time of the G1/S transition as a
result of the activation of cyclin transcription by E2F-family tran-
scription factors (Dyson, 1998) and stabilization of the cyclin pro-
teins via antigen-presenting cell (APC)/CCdh1 inactivation (Reim-
ann et al., 2001). At the end of S phase, the ATR-mediated DNAThis is an open access article under the CC BY-Nreplication checkpoint is turned off and a FOXM1-mediated tran-
scriptional circuit is activated (Lemmens et al., 2018; Saldivar
et al., 2018). At about the same time, the pace of cyclin B1 accu-
mulation (Akopyan et al., 2014; Deibler and Kirschner, 2010;
Frisa and Jacobberger, 2009; Jacobberger et al., 2012; Pines
and Hunter, 1991), as well as the accumulation of other pro-
mitotic regulators, including Plk1, Bora, and Aurora A, increases
(Akopyan et al., 2014; Macurek et al., 2008; Seki et al., 2008).
These changes in transcription and protein abundances are
thought to culminate in the activation of mitotic kinases, espe-
cially Cdk1, and the inactivation of the counteracting phospha-
tases PP1 and PP2A-B55 (Crncec and Hochegger, 2019; Heim
et al., 2017). Cdk1 activity—judged by substrate phosphoryla-
tion—rises throughout G2 phase (Akopyan et al., 2014; Lindqvist
et al., 2007) and sharply increases toward the end of G2 phase
(Akopyan et al., 2014; Gavet and Pines, 2010b). Cdk1-cyclin
B1 then translocates from the cytoplasm to the nucleus just prior
to nuclear envelope breakdown (Hagting et al., 1999; Jin et al.,
1998; Li et al., 1997; Pines and Hunter, 1991; Santos et al., 2012).
The final increase in cyclin B1-Cdk1 activity, and decrease in
PP2A-B55 activity, is thought to be due to the flipping of two bi-
stable switches. Two feedback loops, a double-negative feed-
back loop involving the Cdk1-inhibitory kinases Wee1/Myt1
and a positive feedback loop involving the Cdk1-activating
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Figure 1. Measuring the Duration of Cell Cy-
cle Phases Using Fluorescently Labeled
PCNA and Histone H2B in MCF10A Cells
(A) Schematic of the regulation of Cdk1 activity at
the G2/M transition by cyclins and multiple feed-
back loops. The protein synthesis inhibitor cyclo-
heximide (CHX) can block cyclin accumulation; it
also activates p38 MAPK, which can delay G2/M
progression by inhibiting Cdc25 and/or potentially
activating Wee1/Myt1 (Reinhardt and Yaffe, 2009).
The small-molecule inhibitors SB202190 and
SB203580 and PD0166285 and MK-1775 have
been used in this study to inhibit p38 MAPK or
Wee1/Myt1 activity, respectively.
(B) eYFP-PCNA can be used to determine the
onset of S phase, the completion of S phase, and
the onset of mitosis (nuclear envelope break-
down); histone H2B-mTurquoise (used here) or
histone H2B-mCherry can be used to determine
anaphase onset. Scale bars: 10 mm.
(C) Three examples of cells showing the disap-
pearance of eYFP-PCNA foci (yellow arrows) at the
end of S phase. Times (in the format h:min) were
aligned to the time of entry into G2 phase. Scale
bars: 10 mm.
(D) Frequency distributions of G2 phase duration
measured in MCF10A cells expressing H2B-
mCherry and eYFP-PCNA either in the absence
(‘‘medium,’’ gray; n = 104) or presence of 0.1%




OPEN ACCESSreached a threshold concentration, beyond which the system
switches from low to high Cdk1 activity and high to low Wee1/
Myt1 activity (Figure 1A; Novak and Tyson, 1993; Pomerening
et al., 2003; Sha et al., 2003). At the same time, a double-nega-
tive feedback loop centered on PP2A-B55 flips and leads to an
abrupt decrease of PP2A-B55 activity (Gharbi-Ayachi et al.,
2010; Mochida et al., 2010, 2016; Rata et al., 2018; Vinod and
Novak, 2015).
The cyclin B1 threshold concentration is determined by the
amounts of Cdc25 and Wee1/Myt1 activity present (Tsai et al.,
2014). In somatic cells, several signaling pathways impinge
upon Cdc25 and/or Wee1 to delay the G2-to-M transition in
the face of stresses (Reinhardt and Yaffe, 2009). These include
the ATM/ATR kinases, which activate Chk1 and Chk2, which in
turn can inactivate Cdc25 and activateWee1 by phosphorylating
14-3-3 binding sites in the two Cdk1 regulators. These pathways2 Cell Reports 32, 107901, July 14, 2020play a role in delaying mitosis in the pres-
ence of DNA damage and may also help
prevent premature mitosis in cells
undergoing normal DNA replication
(Blackford and Jackson, 2017; Lemmens
et al., 2018; Reinhardt and Yaffe, 2009;
Saldivar et al., 2017). In addition, a protein
kinase cascade that includes the MKK3
and MKK6 mitogen-activated protein
(MAP) kinase kinases, p38 MAP kinase
(MAPK), and the downstream kinase
MAPKAP kinase 2 (MK2) has been impli-cated in restricting the activity of mitotic kinases during DNA
replication and blocking mitotic entry in response to cellular
stress by phosphorylating and therefore inhibiting Cdc25 via
the same 14-3-3 binding site (Lemmens et al., 2018; Manke
et al., 2005; Matsusaka and Pines, 2004). Interestingly, p38 acti-
vation has been observed in response to protein synthesis
stresses, including cycloheximide (Kyriakis et al., 1994); indeed,
cycloheximide is often used as a positive control for maximal
activation of p38. These findings raise the question of whether
the cycloheximide-dependent G2 delay is caused by blocking
the synthesis of proteins required for mitotic entry or rather acti-
vation of the p38-dependent G2/M checkpoint.
Here, we used live-cell markers of cell cycle progression com-
bined with small-molecule inhibitors to dissect the contribution
of protein synthesis to G2 and mitotic progression. We show
that inhibition of Wee1/Myt1 shortens the duration of G2 phase
Article
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OPEN ACCESSin a dose-dependent manner and allows cells to progress into
mitosis in the presence of cycloheximide. Moreover, p38 inhibi-
tion overcomes a cycloheximide-induced G2 arrest, arguing that
p38-mediated checkpoint activation causes the arrest and not
insufficient protein synthesis. However, althoughG2 protein syn-
thesis is not required for mitotic entry, it is required for normal
mitotic progression. These findings suggest that the burst of cy-
clin synthesis that normally occurs during G2 phase serves as a
‘‘just-in-time’’ preparation for mitotic progression but does not
trigger mitotic entry.RESULTS
We chose MCF10A cells, a spontaneously immortalized human
mammary epithelial cell line, for these studies, because they
are euploid, non-tumorigenic, and have been studied extensively
(Debnath et al., 2003; Soule et al., 1990). To determine when S
phase ends and G2 phase begins, we stably expressed an
eYFP-PCNA (proliferating cell nuclear antigen) fusion protein, a
live-cell marker of DNA replication (Hahn et al., 2009; Leonhardt
et al., 2000; Zerjatke et al., 2017). eYFP-PCNA forms bright foci
within the nucleus during S phase, which become brighter and
less numerous as S phase progresses (Figures 1B and 1C). At
the end of S phase, eYFP-PCNA foci dissolve and fluorescence
becomes diffuse, marking the S/G2 transition (Figure 1C). Upon
nuclear envelope breakdown (NEB), nuclear eYFP-PCNA dis-
perses throughout the cell; this can be taken as a marker for
the G2/M transition (or, more precisely, of the prophase/prome-
taphase transition; Figure 1B). Thus, eYFP-PCNA proved to be
well suited to measure G2 duration, from the time of G2 onset
(the disappearance of foci) to the time of G2 termination (taken
as the time when eYFP-PCNA exited the nucleus due to NEB;
Zerjatke et al., 2017). In addition, we stably expressed histone
H2B fused to a fluorescent protein in order to monitor the
different stages of mitotic progression (Figure 1B).
Typical mean G2 durations were found to be 4 h with a stan-
dard deviation of 42 min (Figure 1D). This is within the range of
previously reported durations for G2 phase in a variety of cell
lines (Akopyan et al., 2014; Araujo et al., 2016; Baserga, 1985;
Essers et al., 2005; Gerlich et al., 2006; Hahn et al., 2009).
Because many of our subsequent experiments required the
addition of DMSO-solubilized drugs to a final DMSO concentra-
tion of 0.1%, we ensured that this concentration of DMSO does
not measurably impact G2 progression (Figure 1D).Live-Cell Imaging Confirms that Cycloheximide Blocks
Entry into Mitosis
Early studies on fixed cells showed that the protein synthesis in-
hibitors puromycin and cycloheximide cause cells to arrest in G2
phase (Donnelly and Sisken, 1967; Verbin and Farber, 1967). We
confirmed this finding by live-cell microscopy using the PCNA
probe to demarcate G2 phase. We followed asynchronously
growing cells in cell culture for 4–6 h and then added cyclohex-
imide (10 mg/mL) and continued to follow the cells for another
6–10 h (Figure 2A). This allowed us to identify cells that had
exited S phase during the initial imaging period, determine accu-
rately how much time these cells had spent in G2 phase prior todrug addition, and finally determine the fate of these cells in
response to the drug treatment.
Cells treated with DMSO alone progressed into mitosis (130
out of 130 cells), but cycloheximide addition arrested the large
majority of cells (153 cells out of 165) in G2 phase (Figures
2B–2D). Cycloheximide-treated cells were more likely to prog-
ress into mitosis if the drug was added late in G2 phase. Of
the 12 cycloheximide-treated cells that did enter mitosis, 10
had spent more than 3 h in G2 phase (>75% of the duration
of a normal G2 phase) at the time of cycloheximide addition
(Figures 2C and 2D). Based on logistic regression analysis,
the probability that a cycloheximide-treated cell will enter
mitosis if the cycloheximide is added 2 h after the start of G2
phase is 1% (with a 95% confidence interval [CI] of 0%–7%);
if added 3 h after the start of G2 phase, it rises to 4% (95%
CI 1%–11%), and if it is added 4 h after the start of G2 phase,
the duration of a typical normal G2 phase, the probability is
19% (95% CI 6%–45%; Figure 2E). The fraction of mitotic cells
in the cell population (mitotic index) remained approximately
constant throughout the experiment for the DMSO-treated pop-
ulation but decreased to near-zero within 60 min after cyclohex-
imide treatment (Figure 2F). Together, these findings confirm
that cycloheximide-treated G2 cells do arrest, as previously
noted (Donnelly and Sisken, 1967; Verbin and Farber, 1967),
and imply that cells remain sensitive to cycloheximide treatment
until late in G2 phase.
Wee1/Myt1 Inhibition Shortens G2 Phase and Restores
Mitotic Entry in Cycloheximide-Treated G2 Phase Cells
The Wee1/Myt1 kinases are key regulators of the G2/M transi-
tion that, when active, restrain Cdk1-cyclin B activity. Fluores-
cence resonance energy transfer (FRET) studies have indicated
that Cdk1 activation begins just prior to the nuclear transloca-
tion of Cdk1-cyclin B1—thus very late in G2 phase—which sug-
gests that Wee1 and Myt1 may be active during almost all of G2
phase (Gavet and Pines, 2010a, 2010b). However, other studies
have suggested that some Cdk1 activation can be detected
early in G2 phase (Akopyan et al., 2014), which could mean
that Wee1/Myt1 is switched off earlier. These possibilities can
be distinguished by determining how much the duration of G2
phase can be shortened by Wee1/Myt1 inhibition. In the former
case, the minimal duration of G2 phase would be near zero; in
the latter case, it would be longer, with the minimal duration
of G2 phase corresponding to how long the interval normally
is between the inactivation of Wee1/Myt1 and the onset of
M phase.
We used two small-molecule inhibitors, MK-1775 and
PD0166285, to inhibit Wee1 and Wee1/Myt1 activity, respec-
tively. MK-1775 inhibits Wee1 with a half maximal inhibitory con-
centration (IC50) of 5.2 nM and 100-fold selectivity over Myt1
(Hirai et al., 2009). PD0166285 is an inhibitor of both Wee1 and
Myt1 and so may inhibit Cdk1 Tyr 15 more completely than
MK-1775 does. However, it also inhibits the upstream kinase
Chk1, although with a higher IC50 value (reported IC50 values of
24 nM for Wee1, 72 nM for Myt1, and 3.4 mM for Chk1; Wang
et al., 2001). Treating an asynchronously growing cell culture
with different concentrations of MK-1775 or PD0166285
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Figure 2. Cycloheximide Blocks Entry into Mitosis
(A) Schematic of the experimental setup: asynchronously grown cells were imaged for 4–6 h in order to determine the time when cells exited S phase. After this
period, DMSO or small-molecule inhibitors were added, and cells were followed for another 6–12 h to determine whether and when cells entered and progressed
through mitosis.
(B and C) Montages of MCF10A cells expressing H2B-mCherry and eYFP-PCNA followed over the time course of the experiment described in (A). Times (in the
format h:min) were aligned to the point of DMSO or cycloheximide addition. Four cells are shown that had spent different amounts of time in G2 phase at the time
of cycloheximide addition and subsequently either arrested in G2 phase (B) or entered mitosis (C).
(D) Cell cycle progression in MCF10A cells expressing H2B-Turquoise and eYFP-PCNA and treated with DMSO (left; n = 130) or CHX (right; n = 165). Each row
represents timing data from a single cell. The majority of cells treated with cycloheximide arrested in G2 phase.
(E) Logistic regression analysis. This estimates the probability of a cell enteringmitosis as a function of howmuch time the cell had spent in G2 phase at the time of
drug addition, for the experiment shown in (D). Circles indicate the fraction of cells that enteredmitosis by 5.5 h after entry into G2 phase; this cutoff was the time at
which 95% of the DMSO-treated control cells had entered mitosis. The solid lines show the logistic fit for the data, and the lightly colored areas indicate the 95%
confidence intervals.
(F) Mitotic indices for MCF10A cells expressing H2B-Turquoise and eYFP-PCNA cells treated with DMSO or CHX. Shown are two independent experiments
(circles and triangles, respectively). At least 3,605 cells were counted for each time point.
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OPEN ACCESS15 in a dose-dependent manner (Figure 3A), with a greater effect
obtained with the Wee1/Myt1 inhibitor PD0166285 than with the
more potent Wee1-only inhibitor MK-1775.4 Cell Reports 32, 107901, July 14, 2020Wefirst investigated the impact of theWee1-only inhibitorMK-
1775 on the duration of G2 phase by live-cell imaging. Cells were
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Figure 3. Wee1 Inhibition byMK-1775 Shortens G2 Phase and Restores Mitotic Entry in a Fraction of Cycloheximide-Treated G2 Phase Cells
(A) Asynchronously growing MCF10A cells were treated with DMSO, different concentrations of the Wee1 inhibitor MK-1775 or the Wee1/Myt1-inhibitor
PD0166285 for 1 h. The phosphorylation state of tyrosine 15 of Cdk1 as ameasure of Wee1/Myt1 activity was analyzed by immunoblotting. a-tubulin was used as
loading control. Uncropped immunoblots are shown in Figure S6A.
(legend continued on next page)






OPEN ACCESSMK-1775, and 52–100 cells that entered and completed G2
phase over a 10-h imaging period were tracked and their G2 du-
rations determined. MK-1775 shortened G2 phase in a graded
fashion. The highest concentration of MK-1775 (2 mM) resulted
in a G2 duration of 116 ± 27 min compared to 242 ± 41 min in
the DMSO-treated cells (mean ± SD; Figure 3B). The finding
that Wee1 inhibition by MK-1775 gradually shortens but does
not abolish G2 phase in MCF10A cells suggests that Wee1 is
required for keeping cells from entering M phase, at least in
the latter half of G2 phase.
Considering the central role of Wee1 in controlling G2/M, we
asked whether Wee1 inhibition was able to overcome the cyclo-
heximide-induced G2 arrest. We used the same experimental
setup as described in Figure 2A but, after the initial imaging
period, added DMSO, cycloheximide, 1 mM MK-1775, or cyclo-
heximide plus 1 mM MK-1775 to the cells. Again (cf. Figure 2D),
cells treated with DMSO progressed into mitosis with normal
G2 duration, whereas cycloheximide prevented most cells from
entering mitosis (Figures 3C–3E and S1A). Consistent with the
idea that Wee1 inhibition shortens G2 phase, a majority of cells
(72/105) treated with MK-1775 entered mitosis within 1 h of
drug treatment (compared to 26/100 for theDMSO-treated cells).
Cells that were treated with MK-1775 late in G2 phase tended to
enter mitosis more quickly than those treated early in G2 phase
(Figure S1B). The fraction of cells in mitosis spiked about 3-fold
within the first hour ofMK-1775 treatment (Figure 3F) but returned
to baseline around 3 h after drug addition. Strikingly, whereas
cycloheximide blockedmitotic entry inmost cells (92/103), about
half of the cells (55/105) treated with cycloheximide plus 1 mM
MK-1775 entered mitosis. The probability of a cell entering
mitosis in the presence of cycloheximide depended on the time
the cell had spent in G2 phase prior to drug addition and
increased sharply if cells had spent at least 1.5 to 2 h in G2 phase
(Figure 3E). As we had observed for cells treated with the Wee1
inhibitor alone, the mitotic index for cells treated with MK-1775
plus cycloheximide showed a pronounced spike within the first
hour of treatment; however, the spike decayed to zero within
the next hour. Higher concentrations of MK-1775 (2 mM and
4 mM) mildly increased the percentage of cells entering mitosis
in the presence of cycloheximide but caused severe mitotic de-
lays in the presence or absence of cycloheximide (Figure S1C).
Taken together, these data indicate that MK-1775 can partially
override a cycloheximide-induced G2 phase arrest.(B) G2 duration as a function of MK-1775 concentration. The duration of G2 phase
fluorescence microscopy in the presence of DMSO or different concentrations of M
showed a distinct G2 phase were included in this analysis (n > 52 cells for all co
(C) Montages of MCF10A cells expressing H2B-mCherry and eYFP-PCNA followe
format h:min) were aligned to the point of DMSO/drug addition (10 mg/mL CHX a
(D) Cell cycle progression for MCF10A cells expressing H2B-mCherry and eYFP-P
105), or cycloheximide plus MK-1775 (n = 105). Each row represents timing data fr
phase, whereas more of the cells treated with 1 mMMK-1775 in addition to cyclo
underwent abnormal mitoses, often lacking proper metaphase and cytokinesis.
(E) Logistic regression analysis. Probability of a cell entering mitosis as a function
experiment shown in (D). Circles indicate the fraction of cells that entered mitosis
DMSO-treated control cells had entered mitosis. The solid lines show the logist
intervals. Note that the green (MK-1775) data points corresponding to a probabi
(F) Mitotic indices for MCF10A cells expressing H2B-mCherry and eYFP-PCNA t
4,547 cells were counted for each time point.
6 Cell Reports 32, 107901, July 14, 2020We next asked how the Wee1/Myt1 inhibitor PD0166285
compared to the Wee1-only inhibitor MK-1775. Similarly to
MK-1775, PD0166285 shortened G2 phase gradually as the in-
hibitor concentration was increased (Figure 4A), but the short-
ening was more pronounced in the case of PD0166285. A con-
centration of 1 mM PD0166285 resulted in a G2 duration of 38
± 17 min compared to 255 ± 31 min in the DMSO-treated control
(mean ± SD; Figure 4A). The stronger effect of PD0166285
compared to MK-1775 could be due to its inhibition of Myt1,
although it is also possible that inhibition of Chk1 or some other
kinase could contribute.
Likewise, we found that Wee1/Myt inhibition can overcome
the cycloheximide-induced G2 arrest, and the rescue was
more complete than that afforded by MK1775 treatment. Essen-
tially all of the cycloheximide-treated cells were able to enter
mitosis in the presence of PD0166285 (Figures 4B, 4C, and
S2A), and cells progressed into mitosis with similar dynamics
as cells treated with PD0166285 alone (Figures 4E and S2B). In
contrast to cycloheximide treatment alone, the probability of a
cell entering mitosis was ~100% and was independent of the
time the cell had spent in G2 phase at the time of drug addition
(Figure 4D). The override was also observed when cells were
treated with cycloheximide for 2 h prior to the addition of
PD0166285 (Figure S2C).
The MK-1775 and PD0166285 data suggest that the Wee1/
Myt1 switch is normally thrown very late in G2 phase. Moreover,
they indicate that there is sufficient cyclin (and any other proteins
essential for M phase entry) present even early in G2 phase to
allow rapid mitotic entry, provided that Wee1/Myt1 activity is
low. Moreover, the level of Wee1/Myt1 activity determines the
length of G2 phase. These results are consistent with and extend
the findings of previous studies on the effects of Wee1/Myt1 in-
hibition (Araujo et al., 2016; Chang et al., 2016; Heijink et al.,
2015; Krek and Nigg, 1991; Wang et al., 2001).
Cycloheximide Treatment in S Phase Blocks Cell Cycle
Progression, Even in the Absence ofWee1/Myt1 Activity
Previous studies of Wee1 inhibitors have shown that they can
drive chemotherapy-treated and p53 mutant cell lines into
mitosis without completing DNA replication (Aarts et al., 2012;
Chang et al., 2016). Similarly, overexpression of Cdc25B (but
not Cdc25C) has also been reported to drive S phase HeLa cells
into mitosis (Karlsson et al., 1999). To further explore theof cells expressing H2B-mCherry and eYFP-PCNA was measured by live-cell
K-1775. Only cells that had not entered G2 phase at the time of treatment and
nditions).
d over the time course of the experiment described in Figure 2A. Times (in the
nd/or 1 mM MK-1775).
CNA and treated with DMSO (n = 100), cycloheximide (n = 103), MK-1775 (n =
om a single cell. The majority of cells treated with cycloheximide arrested in G2
heximide entered mitosis. Rows marked with a purple square denote cells that
A biological replicate is shown in Figure S1A.
of how long the cell had been in G2 phase at the time of drug addition for the
by 5.3 h after entry into G2 phase; this cutoff was the time at which 95% of the
ic fits for the data, and the lightly colored areas indicate the 95% confidence
lity of 1.0 have been shifted upward to make them more visible.
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Figure 4. Wee1/Myt1 Inhibition by PD0166285 Shortens G2 Phase and Restores Mitotic Entry in Cycloheximide-Treated G2 Phase Cells
(A) The duration of G2 phase was measured by live-cell fluorescence microscopy of cells expressing H2B-mCherry and eYFP-PCNA in the presence of DMSO or
different concentrations of PD0166285. Only cells that had not entered G2 phase at the time of treatment and showed a distinct G2 phase were included in this
analysis (n > 28 cells for all conditions).
(legend continued on next page)






OPEN ACCESSconnection between protein synthesis and M phase entry, we
analyzed the cell cycle progression of cells treated in S phase
with DMSO, cycloheximide, Wee1 or Wee1/Myt1 inhibitor, or
Wee1 or Wee1/Myt1 inhibitor plus cycloheximide. After being
treated with DMSO in S phase, 100% of cells (99/99) entered
G2 phase, and 93% (92/99) of these cells progressed intomitosis
during the 12-h imaging period (Figure 5A). In contrast, only 29%
of cells (29/100) treated with cycloheximide during S phase pro-
gressed into G2 phase (Figure 5A), whereas most other cells (60/
100) continued to display PCNA foci (albeit dimmer foci than
those seen in control cells), suggesting that S phase was never
completed (Figure 5C). None of the cells treated with cyclohex-
imide alone progressed into mitosis (Figures 5A and 5B).
All cells (100/100) treated with 1 mM MK-1775 during S phase
entered G2 phase and progressed into mitosis. We rarely (0/100
for the experiment shown in Figure 5A and 4/102 for a replicate
experiment) observed S phase cells prematurely enteringmitosis
after treatment with 1 mMMK-1775, but the number of these pre-
mature transitions into mitosis increased significantly (24/99
cells) if cells were treated with 4 mM MK-1775 (Figure 5A). Simi-
larly, all cells (99/99) treated with 1 mM PD0166285 during S
phase entered mitosis; 38 of them progressed into mitosis in
the presence of PCNA foci and without displaying a detectable
G2 phase (Figures 5B and 5D). This suggests that, at some
time during S phase, there is enough pro-mitotic activity to drive
cells into mitosis if Wee1 and Myt1 are inhibited. However, most
of the cells that had directly progressed from S phase into
mitosis after PD0166285 addition failed to undergo proper chro-
mosome segregation and cytokinesis (28/38 failures compared
to 3/61 cells which displayed a G2 phase; Figure 5B), and even
those cells that carried out some duration of G2 phase prior to
mitotic entry required more time to progress through mitosis
(Figure 5E). Presumably, this is at least partially due to the cells’
incomplete DNA replication.
Only 35% of cells (35/100) treated with cycloheximide plus
1 mM MK-1775 during S phase entered G2 phase, and none of
these cells enteredmitosis, asmight be expected given that cells
treated with cycloheximide plus MK-1775 early in G2 phase
generally failed to progress into M phase. On the other hand,
the Wee1/Myt1 inhibitor PD0166285 was able to completely
overcome a cycloheximide-induced arrest when cells had
entered G2 at the time of drug addition (Figure 4C). However,
only 32% of cells (34/105) treated in S phase with cycloheximide
plus PD0166285 entered mitosis, 9 of them directly from S
phase. About one-third of the cells (38/105) never completed S(B) Montages of MCF10A cells expressing H2B-mCherry and eYFP-PCNA followe
format h:min) were aligned to the point of DMSO/drug addition (10 mg/mL cycloh
(C) Cell cycle progression for MCF10A cells expressing H2B-mCherry and eYFP-
(n = 100), or cycloheximide plus PD0166285 (n = 111). Each row represents timing
in G2 phase, although cells treated with 1 mM PD0166285 alone or cycloheximide
drug. A biological replicate is shown in Figure S2A.
(D) Logistic regression analysis. Probability of a cell entering mitosis as a function
experiment shown in (C). Circles indicate the fraction of cells that entered mitosis
DMSO-treated control cells had entered mitosis. The solid lines show the logist
intervals. Note that the green (PD0166285) and purple (PD0166285+CHX) data p
them visible.
(E) Mitotic indices for MCF10A cells expressing H2B-mCherry and eYFP-PCNA t
cells were counted for each time point.
8 Cell Reports 32, 107901, July 14, 2020phase, and 19% (20/105) entered G2 phase, but not mitosis.
Frequently, cells that managed to enter mitosis exhibited
extended and qualitatively abnormal mitotic progression (Fig-
ures 5B and 5E). These findings support the hypothesis that
some S phase protein synthesis is required for mitotic entry,
even in the absence of the Cdk1-inhibiting activity of Wee1
and Myt1.
Wee1/Myt1 Counteract Pro-mitotic Activities that
Accumulate during G2 Phase
To further investigate the relationship betweenWee1/Myt1 activ-
ity, G2 duration, and a cell’s ability to enter mitosis, we followed
untreated cells for 6 h, treated cells with cycloheximide for 2 h,
and then added different Wee1/Myt1 inhibitor concentrations
and assessed the cell’s fate (Figures S2C and S2D). At the lowest
concentration of PD0166285 (0.125 mM), only a fraction of cells
(31%; 32/104) progressed into mitosis, and the probability for
a cell to enter mitosis increased as the time the cell had spent
in G2 phase prior to cycloheximide addition increased (Fig-
ure S2D).With increasing PD0166285 concentrations, more cells
were able to enter mitosis, even if they had spent less time in G2
phase prior to drug addition (Figures S2C and S2D). These re-
sults are again consistent with the idea that pro-mitotic activities
accumulate throughout G2 phase and are opposed by Wee1/
Myt1 activity during this time; the later in G2 phase, the more
pro-mitotic activities have accumulated and the less completely
Wee1/Myt1 needs to be inhibited in order to flip the mitotic
switch.
p38 Inhibition Allows Cells to Enter Mitosis in the
Presence of Cycloheximide
The data presented so far are consistent with the hypothesis
that, in G2 phase, cyclin synthesis triggers mitotic entry: cyclo-
heximide blocks mitotic entry, and the effects of MK-1775 and
PD0166285 suggest that some pro-mitotic activity, possibly cy-
clin, gradually accumulates throughout G2 phase. However, it
also remains possible that the ability of cycloheximide to block
mitotic entry is due to its activation of p38MAPK andMK2, rather
than to any effect on cyclin accumulation (Kyriakis et al., 1994;
Reinhardt and Yaffe, 2009).
To address this issue directly, we treated cells with cyclohex-
imide plus one of two p38 MAPK inhibitors (SB202190 and
SB203580) that act as high-affinity inhibitors of p38a and p38b
(MAPK14 and MAPK11) and as lower affinity inhibitors of other
protein kinases (Davies et al., 2000). We verified that, asd over the time course of the experiment described in Figure 2A. Times (in the
eximide [CHX] and/or 1 mM PD0166285).
PCNA and treated with DMSO (n = 113), cycloheximide (n = 116), PD0166285
data from a single cell. Themajority of cells treatedwith cycloheximide arrested
plus 1 mM PD0166285 progressed into mitosis shortly after treatment with the
of how long the cell had been in G2 phase at the time of drug addition for the
by 7.8 h after entry into G2 phase; this cutoff was the time at which 95% of the
ic fits for the data, and the lightly colored areas indicate the 95% confidence
oints corresponding to a probability of 1.0 have been shifted upward to make
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OPEN ACCESSpreviously reported, cycloheximide stimulated the phosphoryla-
tion of p38 and its downstream target Hsp27 and that the inhib-
itors decreased cycloheximide-induced Hsp27 phosphorylation
in a dose-dependent fashion (Figure 6A). We sometimes also
observed a reduction of p38 phosphorylation itself when using
higher inhibitor concentrations (10 and 50 mM), which could be
either an off-target effect or a consequence of feedback in the
regulation of p38 activity (Figure S3A). Tyrosine 15 phosphoryla-
tion of Cdk1 was not impacted by cycloheximide or p38 inhibi-
tion (Figure S3A). The Wee1 inhibitor MK-1775 did not impact
the phosphorylation state of p38 or Hsp27 (Figure S3B). Treating
cells with 1 mMPD0166285, on the other hand, reduced both the
cycloheximide-induced phosphorylation of p38 and Hsp27. The
observed reduction in phosphorylation could be a consequence
of either cross-talk betweenWee1/Myt1 and p38, Chk1 and p38,
or an off-target effect.
Both p38 inhibitors almost completely prevented cyclohexi-
mide from blocking the progression of G2 phase cells into M
phase (Figures 6B and 6C). Whereas only 4 out of 100 cells
treated with cycloheximide alone entered M phase, 83 out of
100 SB202190- and 77 out of 92 SB203580-treated cells did
enter M phase in the presence of cycloheximide (Figure 6C).
For cells treated with cycloheximide alone, the probability of
entering M phase was near zero unless the cells were treated
late in G2 phase (Figures 6C and 6D), as shown earlier (Figures
2E, 3D, and 4C); however, the probability of entering M phase
for cells treated with cycloheximide plus either SB202190 or
SB203580 was 10%–20% for cells treated at the start of G2
phase and rose to near 100% for cells treated 2 h after the start
of G2 phase (Figures 6C and 6D). Overall, 45 out of 95 cells
treated with SB202190 plus cycloheximide and 60 out of 91 cells
treated with SB203580 plus cycloheximide exhibited a normal
G2 phase duration (between the 5th and 95th percentiles of the
G2 durations of DMSO-treated control cells; Figure S3C). How-
ever, a significant fraction of the cells treated early during G2
phase had prolonged G2 durations, whereas cells treated later
in G2 phase mostly exhibited a normal G2 duration (Figure S3D).
The combination of cycloheximide plus SB202190 or SB203580
caused a small increase in the mitotic index followed by a slow
decline to lower levels but rescued the sharp decline in mitotic
cells observed in cycloheximide-treated cultures (Figures 6E
and S4B). The structurally similar but inactive compoundFigure 5. Cycloheximide Treatment in S Phase Blocks Cell Cycle Prog
(A) Cell cycle progression for MCF10A cells expressing H2B-mCherry and eYFP-P
1 mM MK-1775 (n = 100), cycloheximide plus 1 mM MK-1775 (n = 100), or 4 mM M
purple square denote cells that underwent abnormal mitoses, often lacking prop
(B) Cell cycle progression for MCF10A cells expressing H2B-mCherry and eYFP-P
1 mMPD0166285 (n = 99), or cycloheximide plus 1 mMPD0166285 (n = 105). Each r
denote cells that underwent abnormal mitoses, often lacking proper metaphase
(C) Montage of anMCF10A cell expressing H2B-mCherry and eYFP-PCNA treated
became weaker after cycloheximide treatment, yet they never completely disap
h:min) was aligned to the point of cycloheximide addition.
(D) Montage of an MCF10A cell expressing H2B-mCherry and eYFP-PCNA trea
presence of PCNA foci (suggesting that the cell never completed S phase). Time (i
mitotic progression without a proper metaphase and cytokinesis.
(E) Mitotic duration, measured as the time from nuclear envelope breakdown (N
PD0166285, or cycloheximide plus PD0166285. Whereas treatment with PD0166
extended mitosis (see also Figure 7), treatment with these drugs in S phase dram
10 Cell Reports 32, 107901, July 14, 2020SB202474 did not prevent cycloheximide fromblockingMphase
entry (Figure S4). Similar results were obtained in HeLa and
hTERT-RPE1 cells (Figures S4C and S4D).
Thus, the p38MAPK inhibitors SB202190 andSB203580 allow
the majority of the cycloheximide-treated G2 phase cells to
progress into M phase. This suggests that p38-mediated check-
point effects, rather than a lack of protein synthesis per se, are
principally responsible for the arrest of cycloheximide-treated
G2 phase cells.
Cells treatedwith SB202190 or SB203580 alone generally pro-
gressed throughG2 phase normally, although about 12%of cells
showed a prolonged G2 phase (Figure S3C) and a few cells (4/92
and 2/90) failed to enterMphase (Figure 6C). Thus, in normal, un-
perturbed cells, p38 has relatively little effect on G2 duration and
M phase.
Protein Synthesis during G2 Phase Is Required for
Normal Mitotic Progression
So far, we have shown that inhibition of either Wee1/Myt1 or p38
can overcome a cycloheximide-induced arrest and allow G2
phase cells to progress into mitosis in the absence of protein
synthesis. However, the requirements to enter mitosis and to
successfully progress through mitosis might differ (see, e.g.,
Gavet and Pines, 2010b). Consistent with this notion, we had
already observed that cells treated with the Wee1/Myt1 inhibitor
during S phase could enter mitosis (with little or no G2 phase) but
then exhibited pronouncedmitotic errors (Figure 5). In addition, a
few cells treated with cycloheximide plus PD0166285 during G2
phase exhibited very long mitoses (Figure 4D), as did some cells
treated with cycloheximide plus either of the p38 inhibitors
(Figure 6C).
Accordingly, we examined the duration of mitosis in cells
treated in G2 phase with cycloheximide plus either the Wee1 in-
hibitor, the Wee1/Myt1 inhibitor, or one of the p38 inhibitors.
Cells treated with MK-1775 showed some delay in mitotic pro-
gression, with 42.9% of cells exhibiting protracted mitoses,
taken here as mitoses longer than the 95th percentile of mitotic
durations in DMSO-treated cells (Figure 7A). Treatment with
MK-1775 plus cycloheximide also caused some cells to prog-
ress through mitosis more slowly, though the effect was some-
what less pronounced than that seen with MK-1775 alone (Fig-
ure 7A). The milder effect might be due to a smaller fraction ofression, Even in the Absence of Wee1/Myt1 Activity
CNA treated during S phasewith either DMSO (n = 99), cycloheximide (n = 100),
K-1775 alone (n = 99). Each row represents a single cell. Rows marked with a
er metaphase and cytokinesis.
CNA treated during S phase with either DMSO (n = 99), cycloheximide (n = 98),
ow represents timing data from a single cell. Rowsmarkedwith a purple square
and cytokinesis.
with cycloheximide during S phase. In this cell (and most cells), the PCNA foci
peared, suggesting that these cells remained in S phase. Time (in the format
ted with 1 mM PD0166285 during S phase that progressed into mitosis in the
n the format h:min) was aligned to the point of drug addition. Note the abnormal
EB) to anaphase, for cells treated either in G2 phase or S phase with DMSO,
285 or treatment with PD0166285 plus cycloheximide in G2 phase only slightly
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OPEN ACCESSthe cycloheximide plus MK-1775-treated early G2 phase cells
entering mitosis compared with the cells treated with MK-1775
alone (Figure 3E). A substantial fraction of cells treated with
PD0166285 with or without cycloheximide exhibited a pro-
tracted mitosis (47% for PD-treated cells and 58% for cells
treated with PD plus cycloheximide; Figure 7B). Thus, cells that
successfully entered mitosis after Wee1 or Wee1/Myt1 inhibition
in the presence or absence of cycloheximide were, nevertheless,
delayed in their progression through M phase. These results
confirm previous findings that Wee1/Myt1 inhibition extends
the mitotic duration (Araujo et al., 2016). The duration of mitosis
was a dose-dependent function of both MK-1775 and
PD0166285 concentration (Figure 7C). Moreover, the greater
the shortening of G2 phase, the greater the delay in M phase
(compare Figure 7C with Figures 3B, 4A, and S5).
For the p38 inhibitors SB202190 and SB203580, the drugs had
some effect on the duration of mitosis, even in the absence of
cycloheximide; 17% (SB202190) and 4.5% (SB203580) of the
drug-treated cells exhibited a protracted mitosis versus 0% for
the DMSO-treated controls (Figure 7D). This suggests that p38
functionmay contribute toMphase progression in at least a sub-
set of cells. A greater proportion of cells treated with either of the
inhibitors plus cycloheximide exhibited a protracted mitosis
(50% and 34%, respectively), suggesting that the protein syn-
thesis that normally occurs during G2 phase helps cells to prog-
ress through M phase in a timely fashion.
DISCUSSION
Here, we have used live-cell imaging to confirm the decades-old
observation (Donnelly and Sisken, 1967; Verbin and Farber,
1967) that the protein synthesis inhibitor cycloheximide prevents
G2 phase cells from enteringmitosis (Figure 2). Based on logistic
regression analysis, the point of no return—the time at which the
cell becomes refractory to cycloheximide treatment—occurs
only at the end of G2 phase (Figure 2). On a cell biological level,
this timing approximately corresponds to when the antephase
checkpoint is silenced (Pines and Rieder, 2001; Rieder and
Cole, 1998, 2000). On a biochemical level, this is about when
the activity of cyclin B1-Cdk1 rises to maximal levels (Akopyan
et al., 2014; Gavet and Pines, 2010b; Jacobberger et al.,Figure 6. p38 MAPK Inhibition Allows Cells to Enter Mitosis in the Pres
(A) Asynchronously growing cells were treated for 6 h with DMSO, cyclohexim
SB203580. The phosphorylation state of p38 as well as the phosphorylation stat
activation state of p38. Uncropped immunoblots are shown in Figure S6B.
(B) Montages of MCF10A cells expressing H2B-mCherry and eYFP-PCNA follow
cycloheximide or cycloheximide plus either SB202190 or SB203580. Times (in th
(C) Cell cycle progression for MCF10A cells expressing H2B-mCherry and eYFP-P
(n = 90), CHX+SB202190 (n = 95), or CHX+SB203580 (n = 91). Each row represent
arrested in G2 phase, whereas cells treated with CHX plus SB202190 or SB2035
square denote cells that underwent abnormal mitoses, often lacking proper met
(D) Logistic regression analysis. Probability of a cell to enter mitosis as a function o
the experiment shown in (C). Circles indicate the fraction of cells that entered mito
DMSO-treated control cells had entered mitosis. The solid lines show the logis
intervals.
(E) Mitotic indices for MCF10A cells expressing H2B-mCherry and eYFP-PCNA
CHX+SB203580. At least 3,672 cells were counted for each time point.
An additional similar experiment is shown in Figures S4A and S4B.
12 Cell Reports 32, 107901, July 14, 20202012). It is possible that all three of these phenomena are man-
ifestations of the flipping of the bistable Cdk1/PP2A switch
from its interphase to its M phase state.
Both theWee1 inhibitor MK-1775 and theWee1/Myt1 inhibitor
PD0166285 shortened G2 phase in a gradual, concentration-
dependent manner (Figures 3B and 4A). The effects of MK-
1775 and PD0166285 on cell cycle progression have been inves-
tigated previously (Araujo et al., 2016; Chang et al., 2016; Heijink
et al., 2015; Krek and Nigg, 1991; Wang et al., 2001), yet the
combination of acute inhibition using small-molecule inhibitors
and live cell imaging allows us now to understand the dynamic
nature of these effects in more detail. Acute inhibition of Wee1
or Wee1/Myt1 causes cells that have already spent some time
in G2 phase to quickly enter mitosis. This results in a transient
sharp increase in the mitotic cell population (Figures 3F and
4E). Consistent with previous studies, we find that treatment
with 4 mM MK-1775 results in long mitotic delays and an
increased mitotic population (Figure S1C), though we did not
observe delays of a similar magnitude usingmoremoderate con-
centrations of MK-1775 (1 mM) or any concentration of
PD0166285 (Figures 3 and 4). Note that PD0166285 treatment
also resulted in an increasedmitotic population, which appeared
to be mainly caused by cells delayed in mitosis because they
had prematurely entered mitosis without completing DNA
replication.
The cycloheximide effect appears not to be due to the inhibi-
tion of protein synthesis per se but rather to the activation of
p38 MAPKs. Indeed, activation of p38 MAPK in response to pro-
tein synthesis inhibition is well known (Kyriakis et al., 1994),
although the mechanism leading to this activation is not well un-
derstood but might involve induced conformational changes in
the 28S ribosomal subunit and might to some extent be de-
coupled from the inhibition of protein synthesis (Iordanov et al.,
1997; Shifrin and Anderson, 1999). Consistent with this notion,
concentrations of the protein synthesis inhibitor anisomycin
that do only mildly inhibit protein synthesis and other activators
of p38, like H2O2, have been shown to decrease the fraction of
cells in prophase and prometaphase (Matsusaka and Pines,
2004).
Accordingly, the p38 inhibitors SB202190 and SB203580
largely restored mitotic entry in cycloheximide-treated cellsence of Cycloheximide
ide, or cycloheximide plus either of the p38 MAPK inhibitors SB202190 or
e of the p38 substrate Hsp27 was analyzed by immunoblotting to assess the
ed over the time course of the experiment described in Figure 3A treated with
e format h:min) were aligned to the point of drug addition.
CNA treated with DMSO (n = 99), CHX (n = 100), SB202190 (n = 92), SB203580
s timing data from a single cell. Themajority of cells treated with cycloheximide
80 (50 mM) progressed into mitosis in most cases. Rows marked with a purple
aphase and cytokinesis.
f how long the cell has already been in G2 phase at the time of drug addition for
sis by 5 h after entry into G2 phase; this cutoff was the time at which 95% of the
tic fit for the data, and the lightly colored areas indicate the 95% confidence
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Figure 7. Protein Synthesis during G2 Phase Is Required for Normal Mitotic Progression
(A) Frequency distribution of mitotic durations (measured fromNEB to anaphase onset) of cells treated with DMSO (n = 100), 1 mMMK-1775 (n = 105), or CHX plus
1 mMMK-1775 (n = 54) during G2 phase. Cells were considered to exhibit a protracted mitosis if the mitotic duration exceeded the 95th percentile of the mitotic
duration of DMSO-treated cells (>39.5 min). p values were calculated using a nonparametric Mann-Whitney test (****p < 0.0001).
(B) Frequency distribution of mitotic durations (measured from NEB to anaphase onset) of cells treated with DMSO (n = 113), 1 mMPD0166285 (n = 100), or CHX
plus 1 mM PD0166285 (n = 110) during G2 phase. Cells were considered to exhibit a protracted mitosis if the mitotic duration exceeded the 95th percentile of the
mitotic duration of DMSO-treated cells (>30 min). p values were calculated using a nonparametric Mann-Whitney test (*p < 0.05 and ****p < 0.0001).
(legend continued on next page)






OPEN ACCESS(Figures 6, S2, and S3). Likewise, the Wee1 inhibitor allowed
about half of the cycloheximide-treated cells to progress into
mitosis, consistent with the hypothesis that the effects of the
p38 inhibitors are ultimately mediated by the Cdc25 and/or
Wee1/Myt1 proteins (Figure 4). The override was even more pro-
nounced using the Wee1/Myt1 inhibitor PD0166285, possibly
because of the additional effect of this inhibitor on Myt1 and/or
p38 activation. Taken together, these results suggest that G2
phase cyclin synthesis, and G2 phase protein synthesis in gen-
eral, is not strictly required for timely progression into M phase.
Note, however, that, even though G2 phase protein synthe-
sis is not required when p38 or Wee1 and Myt1 are inhibited,
it is theoretically possible that protein synthesis could still be
required when these kinases are not pharmacologically in-
hibited. For example, if there was some p38-inhibitory protein
that was normally synthesized in G2 phase and whose synthe-
sis was normally required for progression into M phase, this
protein synthesis requirement would be expected to be abro-
gated in cells treated with p38 or Wee1/Myt1 inhibitors. How-
ever, there is no affirmative evidence for such a protein, and
p38 inhibition alone, in contrast to Wee1/Myt1 inhibition,
does not alter the duration of G2 phase in the absence of
cycloheximide. Therefore, the simplest interpretation of the
present findings is that the effect of cycloheximide on G2/M
progression is due to checkpoint activation rather than protein
synthesis inhibition.
These findings also suggest that the accelerating accumula-
tion of cyclin B1 that normally begins at about the onset of G2
phase is not the trigger for mitosis, or at least not the only trigger,
because normal G2 durations can be seen in the absence of
such protein synthesis. This conclusion fits well with loss-of-
function studies that show that, even though cyclin B1 is essen-
tial inmouse embryos (Brandeis et al., 1998; Strauss et al., 2018),
substantial inhibition of cyclin B1 synthesis yields relatively sub-
tle delays in the timing of mitotic entry (Gong and Ferrell, 2010;
Gong et al., 2007; Hégarat et al., 2020). Likewise, the current
findings fit well with the observation that cyclin B1 overexpres-
sion has little or no effect on cell cycle dynamics (Resnitzky
et al., 1994). Note that the current findings also suggest that
cell size is probably not the ultimate trigger of mitotic entry,
because cell growth would be expected to be inhibited by pro-
tein synthesis inhibitors.
What then is the trigger for mitosis? One possibility is that the
cessation of some low but non-zero levels of ATR- or ATM-medi-
ated checkpoint signaling (Gong and Ferrell, 2010; Lemmens
et al., 2018; Saldivar et al., 2018) at the S/G2 boundary might
set into motion a signal transduction process that leads to inac-
tivation or degradation of Wee1/Myt1 (Ayad et al., 2003; Michael
and Newport, 1998; Watanabe et al., 2004) and activation of
Cdc25. Consistent with this hypothesis, we observed that the
duration of G2 phase is a sensitive function of the basal level
of Wee1/Myt1 activity (Figures 3B and 4A). Another possibility(C) Mitotic duration was measured for cells that progressed through G2 phase an
1775 or PD0166285. Mitotic duration increased with higher concentrations of MK
(D) Frequency distribution of mitotic durations of cells treated with DMSO (n
CHX+SB203580 (n = 77) during G2 phase. Cells were considered to exhibit a prot
duration of DMSO-treated cells (>30 min). p values were calculated using a nonp
14 Cell Reports 32, 107901, July 14, 2020is that the translocation of cyclin A2 from the nucleus to the cyto-
plasm, an event that occurs during late S phase, may initiate the
events that lead to mitotic entry (Cascales et al., 2017; Jackman
et al., 2002). A third possibility is that the Bora-Aurora A-Plk1
pathway is the critical trigger (Seki et al., 2008; Vigneron et al.,
2018). How exactly cells integrate the different signaling path-
ways in order to decide whether or not to enter mitosis remains
an important, open question in somatic cell cycle regulation.
Cycloheximide-treated cells rescued by p38 MAPK inhibition,
and cells enteringmitosis precociously due toWee1/Myt1 inhibi-
tion, did take longer to progress through and exit mitosis (Fig-
ure 7). In both cases, these cells would be expected to enter
mitosis with lower cyclin B1 levels than normal. The lower cyclin
B1 levels could result in all or some mitotic substrates being
phosphorylated more slowly, resulting in the observed mitotic
delays.
G2 phase protein synthesis, or cyclin B1 synthesis more spe-
cifically, appears to represent ‘‘just-in-time’’ preparation for the
next phase of the cell cycle. This concept, borrowed from supply
chain management, has been proposed to apply to protein syn-
thesis and complex assembly in the bacterial cell cycle (McA-
dams and Shapiro, 2003). Even though the proteins involved in
the bacterial cell cycle bear little resemblance to those that regu-
late the eukaryotic cell cycle, perhaps this concept applies to
both regulatory systems.STAR+METHODS
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Chemicals, Peptides, and Recombinant Proteins
PD0166285 EMD Millipore #513028
Cycloheximide Sigma-Aldrich 01810-5G
SB202474 EMD Millipore #559387
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SB203580 EMD Millipore, #559387
MK-1775 Selleckchem S1525
horse serum GIBCO #16050-114
fetal bovine serum Axenia Biologix #F001
choleratoxin Sigma-Aldrich C8052-2mg
insulin Sigma-Aldrich I1882-100mg
hygromycin B Invitrogen 10687-010
FuGENE6 Promega E2691
Collagen (PureCol) Advanced BioMatrix #5005-100ML
96-well glass bottom plate Cellvis P96-1.5H-N
Experimental Models: Cell Lines
MCF10A Laboratory of Tobias Meyer
HEK293T ATCC CRL-3216
HeLa ATCC CCL-2
hTERT RPE-1 ATCC CRL-3216
MCF10A eYFP-PCNA H2B-mTurquoise This study N/A
MCF10A eYFP-PCNA H2B-mCherry This study N/A
hTERT RPE-1 eYFP-PCNA H2B-mTurquoise This study N/A
HeLa eYFP-PCNA H2B-mTurquoise This study N/A
Recombinant DNA
pTRIP-EF1a (Dardalhon et al., 2001) N/A
pTRIP-EF1a-eYFP-PCNA This study N/A
CSII-EF (Spencer et al., 2013) N/A
CSII-EF- H2B-mTurquoise This study N/A
CSII-EF- H2B-mCherry This study N/A
Software and Algorithms
Mathematica 10 and 12 Wolfram Research https://www.wolfram.com/mathematica/
Graphpad Prism 8.0.2 and 8.4 GraphPad https://www.graphpad.com/scientific-
software/prism/
Fiji (ImageJ, version 2.00-rc-49/1.51e) (Schindelin et al., 2012) https://imagej.net/Fiji
MetaXpress 5.1 software Molecular Devices https://www.moleculardevices.com/
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Excel MIcrosoft N/A
Python 3.7.3 (Van Rossum and Drake, 2009) https://www.python.org/
MATLAB R2015b MathWorks https://www.mathworks.com
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Material Availability
Plasmids and cell lines generated in this study will be made freely available upon request.
Data and Code Availability
The datasets and code supporting the current study are available from the corresponding author on request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture methods
MCF10A human mammary epithelial cells were a kind gift from Sabrina Spencer and were cultured in growth medium DMEM:F12
(GIBCO, #11320-033) containing 5% horse serum (GIBCO, catalog number 16050114), 20 ng/ml EGF (PreproTech, AF-100-15),
0.5 mg/mL hydrocortisone (Sigma-Aldrich, H0888-1g), 100 ng/ml cholera toxin (Sigma-Aldrich, C8052-2mg) 10 mg/ml insulin
(Sigma-Aldrich, I1882-100mg), 1% penicillin, and 1% streptomycin (both from Life Technologies, catalog number 15140-122) as
described previously (Debnath et al., 2003; Soule et al., 1990). HeLa cells (CCL-2) were purchased from the ATCC and cultured in
Dulbecco’s modified Eagle medium containing high glucose and pyruvate (Invitrogen, #11995-073) supplemented with 10% fetal
bovine serum (Axenia Biologix, #F001), 1% penicillin, 1% streptomycin, and 4 mM L-glutamine (all from Gemini Bio-Products,
#400-110). HEK293T cells were obtained from ATCC (CRL-3216) and cultured in the same medium as HeLa. hTERT RPE-1 cells
were obtained from ATCC (CRF-4000) and cultured in DMEM:F12 (GIBCO, catalog number 11320-033), 10% fetal bovine serum
(Axenia Biologix, #F001), 0.01 mg/ml hygromycin B (Invitrogen, 10687-010), 1% penicillin, and 1% streptomycin. All cells were main-
tained at 37C and 5% CO2 and discarded after passage 25.
Stable cell lines
To obtain MCF10A cells stably expressing eYFP-PCNA, we sub-cloned eYFP-PCNA from the eYFP-PCNA construct (Hahn et al.,
2009) into the pTRIP-EF1a lentiviral transfer vector (Dardalhon et al., 2001), kindly provided by Ed Grow at Stanford University, by
using the XbaI and BamHI restriction sites. To make lentivirus, we incubated 1 mL Opti-MEM and 36 mL FuGENE6 for 5 min at
room temperature, then added 10 mg pTRIP-EF1a-eYFP-PCNA, and 6.6 mg pCMVDR8.74, 3.3 mg pMD.G-VSVG, and 3.3 mg pRev
(all kindly provided by Ed Grow), and incubated for 30 min. We used this to transfect HEK293T cells in Opti-MEM for 6 h at 37C
and 5% CO2 and then exchanged with fresh Opti-MEM. We harvested medium containing virus 48 h, 72 h, and 96 h later, filtered
out cell debris with a sterile 0.45-mm filter (Millipore), concentrated by centrifuging for 20 min at 3600 rpm in Amicon-Ultra 15 Filter
Units with a 100,000 kDa MW cutoff (Millipore), and froze down at80C. To transduce MCF10A cells, we added concentrated virus
and 5 mg/ml polybrene (Sigma-Aldrich) to MCF10A cells in growth media, incubated for 24 h, and replaced with growth media. After
culturing cells for 5 more days, we sorted for eYFP-positive cells by fluorescence-activated cell sorting. To obtain MCF10A cells
stably expressing eYFP-PCNA and histone H2B-mCherry or histone H2B-mTurquoise we made lentivirus as above with histone
H2B-mCherry or histone H2B-mTurquoise sub-cloned into the CSII-EF lentiviral transfer vector (Spencer et al., 2013). We used it
to transduce MCF10A cells stably expressing eYFP-PCNA and then sorted for cells positive for both fluorescent proteins using fluo-
rescence-activated cell sorting. The hTERT RPE-1 cells stably expressing eYFP-PCNA and histone H2B-mTurquoise cells were
produced in the same manner.
To obtain HeLa cells stably expressing eYFP-PCNA, we linearized the eYFP-PCNA construct (Hahn et al., 2009) by incubating with
FspI (New England Biolabs) and purifying with ethanol precipitation. We co-transfected linearized eYFP-PCNA and linearized hy-
gromycin marker (Clontech) with FuGENE6 (Promega) at a ratio of 1 mg eYFP-PCNA to 0.1 mg hygromycin marker to 6 mL FuGENE6
according to themanufacturer’s instructions except that we washed cells with Opti-MEM (Invitrogen), transfected cells in Opti-MEM,Cell Reports 32, 107901, July 14, 2020 e2
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more h added 400 mg/ml hygromycin B (Invitrogen). We picked colonies 11 days later using cloning rings and expanded a clone that
had correct PCNA localization in the nucleus and could form PCNA foci.
METHOD DETAILS
Chemical inhibitors
PD0166285 was generously provided by Pfizer and later purchased from EMD Millipore (#513028) and stored frozen as a 25 mM
stock in DMSO (Sigma-Aldrich) and used at a final concentration of 1 mM if not specified differently. Cycloheximide was purchased
from Sigma-Aldrich, stored frozen as a 10 mg/ml stock in water and used at a final concentration of 10 mg/ml. SB202474 (EMDMilli-
pore, #559387) and SB202190 (Sigma, S7067) were stored frozen as 50 mM or 10 mM stock solutions in DMSO. SB203580 (EMD
Millipore, #559387) was stored frozen as a 50 mM stock solution. SB202474, SB202190 and SB203580 were used at a final concen-
tration of 50 mM if not specified differently. MK-1775 was purchased as a 10 mM stock solution in DMSO (Selleckchem, S1525).
Live-cell time-lapse microscopy and image analysis
Cells were seeded into 96-well plates (Costar) or collagen-coated (PureCol, Advanced BioMatrix, #5005-100ML) 96-well glass bot-
tom plate (Cellvis, P96-1.5H-N) the day before microscopy at such a density that they were sub-confluent even at the end of the
experiment. To prevent drying, each well of the plate contained between 100 and 200 mL of growth medium. Images were taken
in 10 min or 15 min intervals, depending on the needs of the experiment, on the ImageXpress Micro System Standard Model (Mo-
lecular Devices) controlled by the MetaXpress 5.1 software (Molecular Devices) using the 10X objective (NA = 0.3, Plan Fluor) or the
20X objective (NA = 0.45, Plan Fluor ELWD). Cells were kept alive inside the microscope in a humidified chamber at 37C and 5%
CO2. We used the YFP-LIVE filter cube for imaging eYFP-PCNA, the CFP-LIVE filter cube for imaging histone H2B-mTurquoise,
the HcRED-LIVE filter cube for imaging histone H2B-mCherry. Combined exposure through all the filter cubes did not exceed
700 msec per frame. We used 4x gain and 1x1 or 2x2 binning.
Raw TIFF images were exported using the MetaXpress 5.1 software (Molecular Devices) and collated into time series by well and
site using a script written in MATLAB (MathWorks) or Python. Cells were tracked manually and each relevant change in a fluorescent
reporter (PCNA focus disappearance, etc.) was recorded in Excel (Microsoft). For some analyses we used a graphical user interface
written in LabView (National Instruments) that recorded the frame number and cell coordinates by responding to a mouse click and
exported results to Excel (Microsoft). To allow features like PCNA foci to be easily perceived, images were typically min-max
adjusted, and we sometimes allowed the H2B-mCherry image to be saturated in the mitotic stages in order to allow the low intensity
H2B-mCherry signal in interphase to be perceivable. A custom-written MATLAB script provided by Tobias Meyer’s laboratory was
used to count the total number of cells in every time frame in order to calculate mitotic indices. False color and merged-channel im-
ages were generated using Fiji (Schindelin et al., 2012).
Immunoblotting and antibodies
2 mL of MCF10A cell suspension at a cell concentration of 1.5 3 105 cells/ml was seeded into a 6-well plate (Falcon, #353046) and
grown for 48 h at 37C. Themediumwas exchanged and the cells were grown for another 6 h. An equal volume of medium containing
the prediluted inhibitors was then added to the cells, and the cells were incubated for 30min (for PD0166285) or 6 h (for cycloheximide
and cycloheximide plus either SB202190 or SB203580). Themediumwas then removed, cells were washed twice with cold PBS and
lysed with lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1x Phosstop #4906845001, 1x cOmplete
#11873580001). Samples were boiled in SDS-PAGE sample buffer and analyzed by SDS-PAGE and immunoblotting. The following
antibodies were used: rabbit a-Cdk1 phospho-Tyr15 (Cell Signaling Technology, #9111L), mouse a-Cdk1 (Santa Cruz Biotech-
nology, #SC-54), mouse a-tubulin (Santa Cruz Biotechnology, #SC-32293), rabbit a-HSP27 phospho-Ser82 (Cell Signaling Technol-
ogy, #2401), mouse a-HSP27 (Cell Signaling Technology, #2402), rabbit a-p38 MAPK (Cell Signaling Technology, #9212) and rabbit
a-p38 MAPK phospho-Thr180/Tyr182 (Cell Signaling Technology, #9211).
QUANTIFICATION AND STATISTICAL ANALYSIS
Logistic regression analysis
Logistic regression analysis is a method for estimating how the probability of a binary outcome—in our case, whether a cell does or
does not ultimately progress into mitosis—varies as a function of time and treatment conditions. The underlying assumption is that
the odds of progressing into mitosis scale multiplicatively with time, which means that the time course data should be approximated
by a logistic function, with parameters for the steepness and time of the transition from low to high probability. We binarized cell
outcomes (i.e., the cell either did or did not progress into mitosis within the average G2 phase duration plus two standard deviations
of the DMSO-treated control), plotted the fraction of cells that attained the outcome as a function of the time of drug addition, and
fitted the data to a logistic function using the LogitModelFit command in Mathematica 10. The 95% confidence bands were calcu-
lated using code deposited in the Mathematica Stack Exchange (https://mathematica.stackexchange.com/questions/26616/
how-can-i-compute-and-plot-the-95-confidence-bands-for-a-fitted-logistic-regres).e3 Cell Reports 32, 107901, July 14, 2020
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Further statistical analyses (e.g., mean, percentiles, nonparametric Mann-Whitney test) were performed using Prism 8.0.2 (Graph-
pad). Statistical parameters, e.g., the number of cells analyzed (n), are described in the figure legends of the respective figure. All
experiments except the immunoblot analyses have been performed in at least two biological replicates – meaning that cells were
freshly plated, imaged, and independently treated with the respective drugs – of which usually one representative experiment is
shown (often – and for all main conclusions - we show a replicate in the Supplemental Information).Cell Reports 32, 107901, July 14, 2020 e4
